

## POLICY Document for Polivy

The overall objective of this policy is to support the appropriate and cost-effective use of the medication, specific to use of preferred medication options, and overall, clinically appropriate use. This document provides specific information to both sections of the overall policy.

### Section 1: Clinical Criteria

- Policy information specific to the clinical appropriateness for the medication

### Section 2: Oncology Clinical Policy

- Policy information specific to regimen review per NCCN Guidelines.

### Section 1: Clinical Criteria

# Specialty Guideline Management Polivy

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Polivy	polatuzumab vedotin-piiq

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- FDA-approved Indications<sup>1</sup>

- Polivy in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
- Polivy in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated

diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.

- **Compendial Uses<sup>1,2</sup>**

- **B-Cell Lymphomas**

- High-grade B-cell lymphomas (HGBLs)
- Monomorphic post-transplant lymphoproliferative disorders (B-cell type)
- Human Immunodeficiency Virus (HIV) Related B-Cell Lymphomas (HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, HIV-related plasmablastic lymphoma, and human herpesvirus-8 (HHV8)-positive diffuse large B-cell lymphoma)
- Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma
- Histological transformation of indolent lymphomas to high-grade B-cell lymphoma with MYC and BCL6 without BCL2 rearrangements
- Diffuse large B-cell lymphoma (DLBCL)

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

- **B-Cell Lymphomas<sup>1,2</sup>**

Authorization of 6 months (up to 6 cycles) may be granted for treatment of B-cell lymphomas with any of the following subtypes:

- Diffuse Large B-cell Lymphoma (DLBCL) when any of the following criteria are met:
  - The requested drug is used as subsequent treatment as a single agent, or in combination with bendamustine and/or rituximab for relapsed or refractory disease when the member is not a candidate for transplant, or the requested medication will be used as a bridging option until CAR T-cell product is available.
  - The requested drug will be used as first line therapy in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) in members who have an International Prognostic Index score greater than 1.
- High-grade B-cell lymphomas (HGBLs) (also referred to as “double-hit” or “triple-hit” lymphomas) when any of the following criteria are met:
  - The requested drug is used as subsequent treatment as a single agent, or in combination with bendamustine and/or rituximab, and member is not a candidate for transplant or the requested medication will be used as a bridging option until CAR T-cell product is available.
  - The requested drug will be used as first line therapy in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) and member has

an International Prognostic Index score greater than 1 and has MYC and BCL6 without BCL2 rearrangements.

- Monomorphic post-transplant lymphoproliferative disorders (B-cell type) when all the following criteria are met:
  - The requested drug is used as subsequent treatment as a single agent, or in combination with bendamustine and/or rituximab, and
  - Member is not a candidate for transplant or the requested medication will be used as a bridging option until CAR T-cell product is available.
- Human Immunodeficiency Virus (HIV) -related B-cell lymphomas (HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, HIV-related plasmablastic lymphoma, and human herpesvirus-8 (HHV8)-positive diffuse large B-cell lymphoma) when all of the following criteria are met:
  - The requested drug is used as subsequent treatment as a single agent, or in combination with bendamustine and/or rituximab, and
  - Member is not a candidate for transplant or the requested medication will be used as a bridging option until CAR T-cell product is available.
- Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma (DLBCL) when any of the following criteria are met:
  - The requested drug is used as subsequent treatment as a single agent, or in combination with bendamustine and/or rituximab, and member is not a candidate for transplant.
  - The requested drug will be used in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) and member has an International Prognostic Index score of 2 or greater.
- Histologic transformation of indolent lymphomas to high grade B-cell lymphoma with MYC and BCL6 and without BCL2 rearrangements when the requested drug will be used in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) and member has an International Prognostic Index score of 2 or greater.

## Continuation of Therapy

Authorization up to 6 months (6 cycles total) may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and who have not received 6 or more cycles of the requested drug.

## **Section 2: Oncology Clinical Policy**

## PURPOSE

The purpose of this policy is to define the Novologix NCCN® Regimen Prior Authorization Program.

## SCOPE

This policy applies to clients who have implemented the Novologix NCCN® Program as a part of their medical and/or pharmacy prior authorization solution.

## PROGRAM DESCRIPTION

The National Comprehensive Care Network® (NCCN®) is an alliance of leading cancer centers devoted to patient care, research and education dedicated to improving the quality, effectiveness, and efficiency of cancer care so patients can live better lives.<sup>1</sup> It is comprised of oncology experts who convene regularly to establish the best treatments for patients. NCCN develops various resources for use by stakeholders in the health care delivery system. These resources include, but are not limited to, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®) and the NCCN Chemotherapy Order Templates (NCCN Templates®).

NCCN Templates® are based on NCCN Guidelines® and NCCN Compendium®. The NCCN Compendium lists the appropriate drugs and biologics as treatment options for specific cancers using U.S. Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. Each recommendation is supported by a level of evidence category.

### NCCN Categories of Evidence and Consensus<sup>2</sup>

- Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
- Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

## POLICY

### Policy for Regimen Prior Authorization

Polivy SGM 3095-A P2024\_R.docx  
Novologix LLC\_NCCN Oncology Clinical Policy\_9.2024

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

A regimen prior authorization allows submission of a single prior authorization request for all oncology drugs or biologics within an NCCN template that require prior authorization.

## PROCEDURE

This policy provides coverage of a regimen review when all of the following criteria are met:

1. Regimen prior authorization reviews, based on NCCN templates, are initiated through the provider portal.
  - If the prior authorization request is submitted via phone or fax, each drug or biologic will need to be submitted and reviewed as a separate prior authorization request for review with drug-specific criteria.
2. The prior authorization review is requested for an oncology drug or biologic.
3. The member is eligible for regimen review.
4. The indication is for a cancer that is eligible for regimen review. Currently, the cancer types in scope for regimen review include the following:
  - o Ampullary Adenocarcinoma
  - o Anal Carcinoma
  - o B-Cell Lymphomas
  - o Basal Cell Skin Cancer
  - o Biliary Tract Cancers
  - o Bone Cancer
  - o Breast Cancer
  - o Bladder Cancer
  - o Central Nervous System Cancers
  - o Cervical Cancer
  - o Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  - o Chronic Myeloid leukemia
  - o Colon Cancer
  - o Dermatofibrosarcoma Protuberans
  - o Esophageal Cancer
  - o Gastric Cancer
  - o Gastrointestinal Stromal Tumors
  - o Gestational Trophoblastic Neoplasms
  - o Hairy Cell Leukemia
  - o Head and Neck Cancers
  - o Histiocytic Neoplasms
  - o Hodgkin Lymphoma
  - o Hepatocellular Carcinoma
  - o Kaposi Sarcoma
  - o Kidney Cancer

- o Melanoma: Cutaneous
- o Melanoma: Uveal
- o Merkel Cell Carcinoma
- o Mesothelioma: Peritoneal
- o Mesothelioma: Pleural
- o Multiple Myeloma
- o Myelodysplastic Syndromes
- o Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions
- o Myeloproliferative Neoplasms
- o Neuroendocrine and Adrenal Tumors
- o Non-Small Cell Lung Cancer
- o Occult Primary
- o Ovarian Cancer
- o Pancreatic Cancer
- o Penile Cancer
- o Primary Cutaneous Lymphomas
- o Prostate Cancer
- o Rectal Cancer
- o Small Bowel Adenocarcinoma
- o Small Cell Lung Cancer
- o Soft Tissue Sarcoma
- o Squamous Cell Skin Cancer
- o Systemic Mastocytosis
- o Systemic Light Chain Amyloidosis
- o T-Cell Lymphomas
- o Testicular Cancer
- o Thymomas and Thymic Carcinomas
- o Thyroid Carcinoma
- o Uterine Neoplasms
- o Vaginal Cancer
- o Vulvar Cancer
- o Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma
- o Wilms Tumor (Nephroblastoma)

In addition, the following criteria must be met for approval:

1. The requested regimen for the drug(s) or biologic(s) and indication is consistent with an NCCN recommendation with a level of evidence category of 1 or 2A.
2. The NCCN template must be accepted by the provider without modification.

Further review may be indicated when the above criteria are not met.

Authorizations may be granted for 12 months or as medically required, based on the member's condition and provider's assessment.

### **Supportive Care: Myeloid Growth Factor Therapy**

Granulocyte colony stimulating factors are recommended for primary prophylaxis based on the febrile neutropenia risk of the chemotherapy regimen. Febrile neutropenia risk levels vary by NCCN Chemotherapy Order template and are listed at the top of the template. Regimens associated with a high or intermediate risk of febrile neutropenia may include a granulocyte colony stimulating factor as part of the prior authorization.

### **Continuation of Therapy**

To submit a request for continuation of therapy, a new regimen prior authorization review must be requested. Upon template selection, the template must be modified to include the appropriate therapies being used for maintenance treatment. The regimen request will be submitted for further review.

### **Dosage and Administration**

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

## **REFERENCES:**

### **SECTION 1**

1. Polivy [package insert]. South San Francisco, CA: Genentech, Inc.; April 2023.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed April 4, 2024.

### **SECTION 2**

1. National Comprehensive Cancer Network. About NCCN website. <https://www.nccn.org/home/about>, accessed September 9, 2024.
2. National Comprehensive Cancer Network. NCCN Categories of Evidence and Consensus website, <https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines>, accessed September 9, 2024.
3. National Comprehensive Cancer Network. NCCN Guidelines website. [https://www.nccn.org/guidelines/category\\_1](https://www.nccn.org/guidelines/category_1), accessed September 9, 2024. (Note: An account may be required.)
4. National Comprehensive Cancer Network. NCCN Drugs and Biologics Compendium website <https://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia>, accessed September 9, 2024. (Note: A subscription may be required.)

5. National Comprehensive Cancer Network. NCCN Chemotherapy Order Templates (NCCN Templates) website. <https://www.nccn.org/compendia-templates/nccn-templates-main/browse-by-cancer-type>, accessed September 9, 2024. (Note: A subscription may be required.)